VERAXA Biotech AG (NASDAQ: VRXA) has announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will lead the advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA accelerates its pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company’s BiTAC technology is designed to address solid tumors, a challenging area in oncology where current therapies have limited efficacy.
For investors, the leadership change signals continued focus on advancing preclinical programs into clinical trials, which could drive future value. The company’s newsroom provides further updates at http://nnw.fm/VRXA.
The full press release is available at https://nnw.fm/cR1RS.
